Ferrer Internacional, S.A.

Barcelona, 21 June 2012

CHMP Chairman
European Medicines Agency
7 Westferry Circus
Canary Wharf
London
E14 4HB
United Kingdom

Subject: **Withdrawal of EGRIFTA (Tesamorelin), 2 mg, powder for solution for injection EMEA/H/C/2427**

Dear CHMP Chairman,

For the withdrawal of initial marketing authorisation application

I would like to inform you that, at this point of time, Ferrer Internacional, S.A. has taken the decision to withdraw the application for Marketing Authorisation of EGRIFTA (Tesamorelin), 2 mg, powder for solution for injection, which was intended to be used for the treatment of excess visceral adipose tissue (VAT), defined as a level greater than 130 cm^2 by imaging procedures, in treatment-experienced adult HIV-infected patients.

This withdrawal is based on the following reason:

The CHMP considers that the data provided do not allow the committee to conclude on a positive benefit risk balance

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMA website.

R.M.B. 15.01.93, Tomo 24875, Folio 163, Hoja nº B-78309,
Inscripción 54ª, N.I.F. A-08041162